Search

Your search keyword '"Ribera, J. M."' showing total 556 results

Search Constraints

Start Over You searched for: Author "Ribera, J. M." Remove constraint Author: "Ribera, J. M."
556 results on '"Ribera, J. M."'

Search Results

1. Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

3. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

4. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

7. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

9. P1702: IMPACT OF CENTER CHARACTERISTICS AND MACROECONOMIC FACTORS ON THE OUTCOME OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC-INSPIRED PROTOCOLS

10. PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

11. P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY

13. Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93

14. PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study

15. Managing hematological cancer patients during the COVID-19 pandemic:an ESMO-EHA Interdisciplinary Expert Consensus

16. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

17. CD34(+)CD19(-)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

18. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

19. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT

21. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

23. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

27. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

31. INTRAVENOUS HIGH DOSE METHOTREXATE AS CENTRAL NERVOUS SYSTEM (CNS) PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) WITH HIGH RISK FOR CNS PROGRESSION

32. BRENTUXIMAB VEDOTIN PLUS CHP AS FIRST‐LINE TREATMENT IN CD30 + PERIPHERAL T‐CELL LYMPHOMAS: REAL LIFE EXPERIENCE FROM A SINGLE INSTITUTION IN SPAIN

33. R‐GDP SCHEDULE IN PATIENTS WITH REFRACTORY OR RELAPSED B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)

35. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

45. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

47. Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis

Catalog

Books, media, physical & digital resources